Some women barely notice menopause beyond a few irregular cycles, while others deal with disruptive hot flashes and night sweats for a decade or more. Multiple large genetic studies, including data from the Women’s Health Initiative and a replication in the UK Biobank, have consistently linked variation in a gene called TACR3 to how frequently women experience hot flashes and night sweats. This finding matters beyond academic interest. The same biological pathway is now the target of an FDA-approved non-hormonal medication, which is a strong sign that the underlying mechanism is real rather than a statistical fluke.
How the TACR3 Gene Shapes Your Brain’s Hot Flash Trigger
TACR3 builds a receptor for a signaling molecule called neurokinin B inside a cluster of hypothalamus neurons that help regulate body temperature. When estrogen drops during menopause, these neurons lose some of the restraint estrogen normally provides and become overactive, flooding the temperature-regulation circuit with neurokinin B signaling. This is understood to be a central driver of the sudden heat sensation and sweating that defines a hot flash.
Genetic variation in TACR3 appears to influence how sensitive this circuit is to that loss of restraint. Research replicated across multiple large cohorts has found specific TACR3 variants associated with meaningfully reduced odds of frequent hot flashes, while this same neurokinin B pathway is now directly targeted by a newer class of medication that blocks the receptor and reduces hot flash frequency and severity. Two women losing estrogen at a similar rate can end up with very different hot flash experiences depending on how reactive this specific brain circuit is to begin with.
Why the CYP19A1 Gene Determines How Much Estrogen Remains After Menopause
After the ovaries largely stop producing estrogen, the body doesn’t drop to zero. A meaningful amount of estrogen continues to be made in fat, muscle, and other peripheral tissue through an enzyme called aromatase, built by the CYP19A1 gene.
Genetic Variation, Not Just Body Fat, Predicts Residual Estrogen
A review of multiple large studies found that specific CYP19A1 variants were consistently associated with differences in circulating estradiol levels in postmenopausal women, independent of the well-known effect of body fat on peripheral estrogen production. In other words, genetics adds its own layer on top of body composition in determining how much estrogen a woman’s body continues generating after her ovaries retire from the job.
Why More Residual Estrogen Doesn’t Always Mean Fewer Symptoms
Having a more active version of this enzyme generally supports higher post-menopausal estrogen levels, which is one plausible piece of why some women experience a gentler symptom transition. It isn’t the whole story, since how sensitively the brain responds to whatever estrogen is present, as seen with TACR3, matters just as much as how much estrogen remains.
The Role of the COMT Gene in Clearing Estrogen Byproducts
The third piece involves what happens to estrogen after it’s used. COMT builds an enzyme that helps break down catechol estrogens, byproducts of estrogen metabolism that can otherwise accumulate.
A study from the Mayo Clinic’s RIGHT 10K cohort found that higher COMT activity was associated with lower severity of physical menopause symptoms, though this association weakened once hormone therapy use was factored in. This is a smaller, more preliminary finding than the TACR3 or CYP19A1 research, and larger studies are needed to confirm it, but it fits with COMT’s known role in clearing hormone byproducts that can otherwise linger and potentially aggravate symptoms.
Genetics Explains the Variation, Not the Experience Itself
None of these genes determine exactly what menopause will feel like for any one woman. Body weight, stress levels, sleep quality, and overall health all interact with this genetic backdrop. What the research does explain is why standard advice and even standard treatments can work dramatically well for one woman and barely touch another’s symptoms, since the underlying biology driving those symptoms isn’t identical from person to person.
If your menopause experience has looked nothing like your friends’ or your mother’s, it may be worth understanding your own hormone-related genetics. A report covering the female hormones pathway can map where your own variants fall.
Frequently Asked Questions
Why do some women get severe hot flashes while others barely notice menopause?
Research has repeatedly linked variation in the TACR3 gene, which affects a brain circuit involved in temperature regulation, to how frequently women experience hot flashes, suggesting some women’s brains are more reactive to the hormonal shift than others.
Does the body really keep making estrogen after menopause?
Yes. An enzyme called aromatase, built from the CYP19A1 gene, continues producing estrogen in fat and other tissues after the ovaries largely stop. Genetic variation in this gene has been linked to differences in circulating estrogen levels in postmenopausal women.
Is the COMT-menopause symptom link well established?
Less so than the TACR3 findings. One cohort study found an association between higher COMT activity and milder physical menopause symptoms, but the association weakened after accounting for hormone therapy use, so this is considered a preliminary finding rather than a settled one.
